Antitumor effect of 2-thio-4-hydrazinouracil on transplantable tumors.
The cytostatic activity of 2-thio-4-hydrazinouracil (THU) on some transplantable tumors has been studied. A strong effect of this compound (between 60% and 100% suppression) has been found in the case of Myeloma P-8 (MOPC-21) and Sarcoma 180 (Crocker). A less pronounced effect has been observed on Yoshida sarcoma, while the development of Jensen sarcoma is not influenced.
D000818:Animals; D004353:Drug Evaluation, Preclinical; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010954:Plasmacytoma / Q000188:drug therapy*; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D012517:Sarcoma, Yoshida / Q000188:drug therapy; D013889:Thiouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity
C011129:2-thio-4-hydrazinouracil; D013889:Thiouracil